Effect of combination of deoxypyridoxine with known anti-proliferative or immunosuppressive agents on lymphocyte serine hydroxymethyltransferase

Measurements of serine hydroxymethyltransferase (SHMT) in resting lymphocyte cultures showed that the level of activity of this enzyme is very low. Under the influence of mitogenic stimuli serine hydroxymethyltransferase activity is induced 5-20-fold. Addition in the cultures of 4-deoxypyridoxine (d...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Postgraduate medical journal 1994, Vol.70 Suppl 1, p.S89-S92
Hauptverfasser: Trakatellis, A, Dimitriadou, A, Exindari, M, Christodoulou, D, Malissiovas, N, Antoniadis, A, Haitoglou, K
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page S92
container_issue
container_start_page S89
container_title Postgraduate medical journal
container_volume 70 Suppl 1
creator Trakatellis, A
Dimitriadou, A
Exindari, M
Christodoulou, D
Malissiovas, N
Antoniadis, A
Haitoglou, K
description Measurements of serine hydroxymethyltransferase (SHMT) in resting lymphocyte cultures showed that the level of activity of this enzyme is very low. Under the influence of mitogenic stimuli serine hydroxymethyltransferase activity is induced 5-20-fold. Addition in the cultures of 4-deoxypyridoxine (dB6), a potent antagonist of vitamin B6 coenzymes, concurrently with the mitogen, inhibits the induction of SHMT. Separate addition in the cultures of four anti-proliferative (AP) and immunosuppressive (IMS) agents, namely actinomycin, cytarabine, asparaginase and cyclosporine, led to the following observations. (1) The AP and IMS agents produce a decrease in the mitogen-induced activity of SHMT. The higher the concentration of the AP/IMS compound, the greater the decrease of enzymatic activity. (2) When a AP/IMS agent is combined with dB6 its effect on SHMT is considerably greater. (3) Ineffective concentrations of AP/IMS agents become effective when combined with dB6. (4) The observed changes in SHMT activity are not, as one would expect, the same in the case of all four drugs. (5) The combination makes it possible to use much smaller doses of these agents with much better results, at least as far as the decrease of enzymic activity is concerned. This is very promising for clinical use of AP agents in cancer chemotherapy and IMS agents in transplantation especially of the heart and lungs, because combining these compounds with dB6 will make possible to use smaller doses over a longer period of time with greater effectiveness.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_76844647</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76844647</sourcerecordid><originalsourceid>FETCH-LOGICAL-p121t-148a390818f9abc85787666472886dc3020c9e018dd34970379c41cc2c71f7b53</originalsourceid><addsrcrecordid>eNotkM1OhDAUhVloxnH0EUy6ckfS0kLL0kzGn2QSN7ompVykSltsizO8hY8sRFYn9-Tc7-aei2SLMc3SnHF6lVyH8IkxoZyRTbLheVbQvNwmv4e2BRWRa5FyptZWRu3sMjbgztMwed24s7aATjp26Mu6k0XSRp0O3vW6BT8v_AByHmljRuvCOAweQlhM-QE2BjTz-skMnVNTBBTAL7huavx8wEDspj56acPCCnCTXLayD3C76i55fzy87Z_T4-vTy_7hmA4kIzElTEhaYkFEW8paiZwLXhQF45kQRaMozrAqARPRNJSVHFNeKkaUyhQnLa9zukvu_7nzH98jhFgZHRT0vbTgxlDxQjA28-bg3RocawNNNXhtpJ-qtUL6ByvYcOo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76844647</pqid></control><display><type>article</type><title>Effect of combination of deoxypyridoxine with known anti-proliferative or immunosuppressive agents on lymphocyte serine hydroxymethyltransferase</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Trakatellis, A ; Dimitriadou, A ; Exindari, M ; Christodoulou, D ; Malissiovas, N ; Antoniadis, A ; Haitoglou, K</creator><creatorcontrib>Trakatellis, A ; Dimitriadou, A ; Exindari, M ; Christodoulou, D ; Malissiovas, N ; Antoniadis, A ; Haitoglou, K</creatorcontrib><description>Measurements of serine hydroxymethyltransferase (SHMT) in resting lymphocyte cultures showed that the level of activity of this enzyme is very low. Under the influence of mitogenic stimuli serine hydroxymethyltransferase activity is induced 5-20-fold. Addition in the cultures of 4-deoxypyridoxine (dB6), a potent antagonist of vitamin B6 coenzymes, concurrently with the mitogen, inhibits the induction of SHMT. Separate addition in the cultures of four anti-proliferative (AP) and immunosuppressive (IMS) agents, namely actinomycin, cytarabine, asparaginase and cyclosporine, led to the following observations. (1) The AP and IMS agents produce a decrease in the mitogen-induced activity of SHMT. The higher the concentration of the AP/IMS compound, the greater the decrease of enzymatic activity. (2) When a AP/IMS agent is combined with dB6 its effect on SHMT is considerably greater. (3) Ineffective concentrations of AP/IMS agents become effective when combined with dB6. (4) The observed changes in SHMT activity are not, as one would expect, the same in the case of all four drugs. (5) The combination makes it possible to use much smaller doses of these agents with much better results, at least as far as the decrease of enzymic activity is concerned. This is very promising for clinical use of AP agents in cancer chemotherapy and IMS agents in transplantation especially of the heart and lungs, because combining these compounds with dB6 will make possible to use smaller doses over a longer period of time with greater effectiveness.</description><identifier>ISSN: 0032-5473</identifier><identifier>PMID: 7526359</identifier><language>eng</language><publisher>England</publisher><subject>Antineoplastic Agents - pharmacology ; Asparaginase - pharmacology ; Cells, Cultured ; Cyclosporine - pharmacology ; Cytarabine - pharmacology ; Dactinomycin - pharmacology ; Glycine Hydroxymethyltransferase - metabolism ; Humans ; Immunosuppressive Agents - pharmacology ; Lymphocytes - drug effects ; Lymphocytes - enzymology ; Pyridoxine - analogs &amp; derivatives ; Pyridoxine - antagonists &amp; inhibitors ; Pyridoxine - pharmacology</subject><ispartof>Postgraduate medical journal, 1994, Vol.70 Suppl 1, p.S89-S92</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4023</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7526359$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Trakatellis, A</creatorcontrib><creatorcontrib>Dimitriadou, A</creatorcontrib><creatorcontrib>Exindari, M</creatorcontrib><creatorcontrib>Christodoulou, D</creatorcontrib><creatorcontrib>Malissiovas, N</creatorcontrib><creatorcontrib>Antoniadis, A</creatorcontrib><creatorcontrib>Haitoglou, K</creatorcontrib><title>Effect of combination of deoxypyridoxine with known anti-proliferative or immunosuppressive agents on lymphocyte serine hydroxymethyltransferase</title><title>Postgraduate medical journal</title><addtitle>Postgrad Med J</addtitle><description>Measurements of serine hydroxymethyltransferase (SHMT) in resting lymphocyte cultures showed that the level of activity of this enzyme is very low. Under the influence of mitogenic stimuli serine hydroxymethyltransferase activity is induced 5-20-fold. Addition in the cultures of 4-deoxypyridoxine (dB6), a potent antagonist of vitamin B6 coenzymes, concurrently with the mitogen, inhibits the induction of SHMT. Separate addition in the cultures of four anti-proliferative (AP) and immunosuppressive (IMS) agents, namely actinomycin, cytarabine, asparaginase and cyclosporine, led to the following observations. (1) The AP and IMS agents produce a decrease in the mitogen-induced activity of SHMT. The higher the concentration of the AP/IMS compound, the greater the decrease of enzymatic activity. (2) When a AP/IMS agent is combined with dB6 its effect on SHMT is considerably greater. (3) Ineffective concentrations of AP/IMS agents become effective when combined with dB6. (4) The observed changes in SHMT activity are not, as one would expect, the same in the case of all four drugs. (5) The combination makes it possible to use much smaller doses of these agents with much better results, at least as far as the decrease of enzymic activity is concerned. This is very promising for clinical use of AP agents in cancer chemotherapy and IMS agents in transplantation especially of the heart and lungs, because combining these compounds with dB6 will make possible to use smaller doses over a longer period of time with greater effectiveness.</description><subject>Antineoplastic Agents - pharmacology</subject><subject>Asparaginase - pharmacology</subject><subject>Cells, Cultured</subject><subject>Cyclosporine - pharmacology</subject><subject>Cytarabine - pharmacology</subject><subject>Dactinomycin - pharmacology</subject><subject>Glycine Hydroxymethyltransferase - metabolism</subject><subject>Humans</subject><subject>Immunosuppressive Agents - pharmacology</subject><subject>Lymphocytes - drug effects</subject><subject>Lymphocytes - enzymology</subject><subject>Pyridoxine - analogs &amp; derivatives</subject><subject>Pyridoxine - antagonists &amp; inhibitors</subject><subject>Pyridoxine - pharmacology</subject><issn>0032-5473</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNotkM1OhDAUhVloxnH0EUy6ckfS0kLL0kzGn2QSN7ompVykSltsizO8hY8sRFYn9-Tc7-aei2SLMc3SnHF6lVyH8IkxoZyRTbLheVbQvNwmv4e2BRWRa5FyptZWRu3sMjbgztMwed24s7aATjp26Mu6k0XSRp0O3vW6BT8v_AByHmljRuvCOAweQlhM-QE2BjTz-skMnVNTBBTAL7huavx8wEDspj56acPCCnCTXLayD3C76i55fzy87Z_T4-vTy_7hmA4kIzElTEhaYkFEW8paiZwLXhQF45kQRaMozrAqARPRNJSVHFNeKkaUyhQnLa9zukvu_7nzH98jhFgZHRT0vbTgxlDxQjA28-bg3RocawNNNXhtpJ-qtUL6ByvYcOo</recordid><startdate>1994</startdate><enddate>1994</enddate><creator>Trakatellis, A</creator><creator>Dimitriadou, A</creator><creator>Exindari, M</creator><creator>Christodoulou, D</creator><creator>Malissiovas, N</creator><creator>Antoniadis, A</creator><creator>Haitoglou, K</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>1994</creationdate><title>Effect of combination of deoxypyridoxine with known anti-proliferative or immunosuppressive agents on lymphocyte serine hydroxymethyltransferase</title><author>Trakatellis, A ; Dimitriadou, A ; Exindari, M ; Christodoulou, D ; Malissiovas, N ; Antoniadis, A ; Haitoglou, K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p121t-148a390818f9abc85787666472886dc3020c9e018dd34970379c41cc2c71f7b53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Antineoplastic Agents - pharmacology</topic><topic>Asparaginase - pharmacology</topic><topic>Cells, Cultured</topic><topic>Cyclosporine - pharmacology</topic><topic>Cytarabine - pharmacology</topic><topic>Dactinomycin - pharmacology</topic><topic>Glycine Hydroxymethyltransferase - metabolism</topic><topic>Humans</topic><topic>Immunosuppressive Agents - pharmacology</topic><topic>Lymphocytes - drug effects</topic><topic>Lymphocytes - enzymology</topic><topic>Pyridoxine - analogs &amp; derivatives</topic><topic>Pyridoxine - antagonists &amp; inhibitors</topic><topic>Pyridoxine - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Trakatellis, A</creatorcontrib><creatorcontrib>Dimitriadou, A</creatorcontrib><creatorcontrib>Exindari, M</creatorcontrib><creatorcontrib>Christodoulou, D</creatorcontrib><creatorcontrib>Malissiovas, N</creatorcontrib><creatorcontrib>Antoniadis, A</creatorcontrib><creatorcontrib>Haitoglou, K</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Postgraduate medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Trakatellis, A</au><au>Dimitriadou, A</au><au>Exindari, M</au><au>Christodoulou, D</au><au>Malissiovas, N</au><au>Antoniadis, A</au><au>Haitoglou, K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of combination of deoxypyridoxine with known anti-proliferative or immunosuppressive agents on lymphocyte serine hydroxymethyltransferase</atitle><jtitle>Postgraduate medical journal</jtitle><addtitle>Postgrad Med J</addtitle><date>1994</date><risdate>1994</risdate><volume>70 Suppl 1</volume><spage>S89</spage><epage>S92</epage><pages>S89-S92</pages><issn>0032-5473</issn><abstract>Measurements of serine hydroxymethyltransferase (SHMT) in resting lymphocyte cultures showed that the level of activity of this enzyme is very low. Under the influence of mitogenic stimuli serine hydroxymethyltransferase activity is induced 5-20-fold. Addition in the cultures of 4-deoxypyridoxine (dB6), a potent antagonist of vitamin B6 coenzymes, concurrently with the mitogen, inhibits the induction of SHMT. Separate addition in the cultures of four anti-proliferative (AP) and immunosuppressive (IMS) agents, namely actinomycin, cytarabine, asparaginase and cyclosporine, led to the following observations. (1) The AP and IMS agents produce a decrease in the mitogen-induced activity of SHMT. The higher the concentration of the AP/IMS compound, the greater the decrease of enzymatic activity. (2) When a AP/IMS agent is combined with dB6 its effect on SHMT is considerably greater. (3) Ineffective concentrations of AP/IMS agents become effective when combined with dB6. (4) The observed changes in SHMT activity are not, as one would expect, the same in the case of all four drugs. (5) The combination makes it possible to use much smaller doses of these agents with much better results, at least as far as the decrease of enzymic activity is concerned. This is very promising for clinical use of AP agents in cancer chemotherapy and IMS agents in transplantation especially of the heart and lungs, because combining these compounds with dB6 will make possible to use smaller doses over a longer period of time with greater effectiveness.</abstract><cop>England</cop><pmid>7526359</pmid></addata></record>
fulltext fulltext
identifier ISSN: 0032-5473
ispartof Postgraduate medical journal, 1994, Vol.70 Suppl 1, p.S89-S92
issn 0032-5473
language eng
recordid cdi_proquest_miscellaneous_76844647
source MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection
subjects Antineoplastic Agents - pharmacology
Asparaginase - pharmacology
Cells, Cultured
Cyclosporine - pharmacology
Cytarabine - pharmacology
Dactinomycin - pharmacology
Glycine Hydroxymethyltransferase - metabolism
Humans
Immunosuppressive Agents - pharmacology
Lymphocytes - drug effects
Lymphocytes - enzymology
Pyridoxine - analogs & derivatives
Pyridoxine - antagonists & inhibitors
Pyridoxine - pharmacology
title Effect of combination of deoxypyridoxine with known anti-proliferative or immunosuppressive agents on lymphocyte serine hydroxymethyltransferase
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T08%3A04%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20combination%20of%20deoxypyridoxine%20with%20known%20anti-proliferative%20or%20immunosuppressive%20agents%20on%20lymphocyte%20serine%20hydroxymethyltransferase&rft.jtitle=Postgraduate%20medical%20journal&rft.au=Trakatellis,%20A&rft.date=1994&rft.volume=70%20Suppl%201&rft.spage=S89&rft.epage=S92&rft.pages=S89-S92&rft.issn=0032-5473&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E76844647%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76844647&rft_id=info:pmid/7526359&rfr_iscdi=true